Document is current
Any future updates will be listed below
-
Authors
Borrelli, Enrico https://orcid.org/0000-0003-2815-5031
Boscia, Francesco
Lanzetta, Paolo https://orcid.org/0000-0003-3746-141X
Lupidi, Marco https://orcid.org/0000-0002-6817-2488
Mastropasqua, Rodolfo
Nicolò, Massimo
Parravano, Mariacristina
Ricci, Federico
Staurenghi, Giovanni
Vadalà, Maria https://orcid.org/0000-0002-2726-698X
Viola, Francesco https://orcid.org/0000-0003-1208-913X
Vujosevic, Stela https://orcid.org/0000-0001-6773-9967
Bandello, Francesco https://orcid.org/0000-0003-3238-9682
- License Information
-
More Information
Article History
Received: 13 January 2025
Revised: 22 July 2025
Accepted: 8 September 2025
First Online: 25 September 2025
Competing interests
: EB is a member of the Eye editorial board. EB: AbbVie; Bayer; Espansione; EyePoint; Novartis; Ocular Therapeutix; Hofmann La Roche; Zeiss. FB: Abbvie, Alcon, Bayer, Hofmann La Roche. PL: Adverum, Aerie, Abbvie, Annexon, Apellis, Bausch & Lomb, Bayer, Biogen, Boehringer Ingelheim, Eyebio, Eyepoint Pharmaceuticals, I-Care, Genentech, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Hofmann La Roche. ML: Abbvie, Apellis, Bayer, Novartis, Hofmann La Roche, Heidelberg Engineering. RM: None. MN: None. MP: Abbvie, Novartis, Bayer, Hofmann La Roche, Zeiss. FR: Abbvie, Apellis, Astellas, Bayer, Genetech, MS&D, Novartis, Regeneron, Hofmann La Roche. GS: Abbvie, Apellis Pharmaceuticals, Inc., Annexon Bioscience, Bayer Healthcare Pharmaceuticals, Boehringer, Centervue, Inc., Genentech, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Medscape, Novartis Pharmaceuticals, Optos, Inc., and RetinAI. MV: Abbvie, Novartis, Bayer, Hofmann La Roche, Zeiss. FV: None. SV: Abbvie, Adverum, Alimera, Annexon, Apellis, Bayer, Boehringer & Ingelheim, Novartis, Roche, Zeiss. FB: Abbvie, Alimera, Bayer, Boehringer-Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, Ntc Pharma, Oxurion Nv, Sifi.
